Vistagen Therapeutics, Inc. (VTGN) — SEC Financial Statements & Analysis

Vistagen Therapeutics, Inc. (VTGN) is a pharmaceutical preparations company, incorporated in NV. Vistagen Therapeutics, Inc. trades on Nasdaq as: VTGN. Vistagen Therapeutics, Inc. (VTGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Vistagen Therapeutics, Inc. carries a market cap of $9.89M, a P/E ratio of -0.15x, a P/B ratio of 0.40x, a P/S ratio of 3.95x, an enterprise value of $-7.11M, and an EV/EBITDA multiple of 0.10x. On profitability, it posts an operating margin of -2785.69%, a net margin of -2703.72%, a Return on Equity (ROE) of -166.46%, a Return on Assets (ROA) of -129.22%, and a Return on Invested Capital (ROIC) of -856.55%. Per share, it reports EPS of $-1.57, diluted EPS of $-1.57, free cash flow per share of $-1.45, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 287.15% year-over-year, net income growth of 21.23% year-over-year, and EPS growth of -9.94% year-over-year. On the balance sheet, it maintains a current ratio of 3.07x, a quick ratio of 2.84x, working capital of $23.12M, a debt-to-equity ratio of 0.46x, a debt ratio of 0.31, an interest coverage ratio of -34.00x, free cash flow of $-62.30M (TTM), and net debt of $-16.99M. Figures sourced from SEC EDGAR.

Market Cap

$9.89M

P/E TTM

-0.15x

EPS TTM

$-1.57

P/B TTM

0.40x

ROE TTM

-166.46%

ROA TTM

-129.22%

Debt To Equity

0.46x

Free Cash Flow TTM

$-62.30M

Net Revenue TTM Growth 1Y

287.15%

Data as of 2026-06-30 · Source: SEC EDGAR